Trial Profile

A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Adverse reactions; Therapeutic Use
Acronyms T-SCAN study

Most Recent Events

12 Mar 2022 Results published in the Investigational New Drugs
17 Jan 2021 Results assessing recommended dose of trifluridine/tipiracil and irinotecan presented at the 2021 Gastrointestinal Cancers Symposium
19 Aug 2020 Planned End Date changed from 31 May 2019 to 31 May 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com